Skip to main content
PMC home page
British Medical Journal logoLink to British Medical Journal
. 1975 Jun 28;2(5973):714–715. doi: 10.1136/bmj.2.5973.714

Controlled clinical trial of L-dopa and nafoxidine in advanced breast cancer: an E.O.R.T.C. study.

E Engelsman, J C Heuson, J Blonk Van Der Wijst, A Drochmans, H Maass, F Cheix, L G Sobrinho, H Nowakowski
PMCID: PMC1673916  PMID: 1095122

Abstract

L-Dopa lowers plasma prolactin levels, and there have been reports that patients with advanced breast cancer have been successfully treated with L-dopa. To test the potential value of L-dopa in this disease a randomized clinical trial of L-dopa and nafoxidine (as the reference compound) was conducted in postmenopausal women with advanced breast cancer. Objective remissions were obtained in sever out of 36 patients (19%) treated with nafoxidine but in none out of 40 patients treated with L-dopa. L-Dopa in the dose schedule used seems to be ineffective in advanced breast cancer.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boot L. M. Prolactin and mammary gland carcinogenesis. The problem of human prolactin. Int J Cancer. 1970 Mar 15;5(2):167–175. doi: 10.1002/ijc.2910050202. [DOI] [PubMed] [Google Scholar]
  2. Heuson J. C., Engelsman E., Blonk-Van Der Wijst J., Maass H., Drochmans A., Michel J., Nowakowski H., Gorins A. Comparative trial of nafoxidine and ethinyloestradiol in advanced breast cancer: an E.O.R.T.C. study. Br Med J. 1975 Jun 28;2(5973):711–713. doi: 10.1136/bmj.2.5973.711. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Heuson J. C., Engelsman E., Blonk-Van Der Wijst J., Maass H., Drochmans A., Michel J., Nowakowski H., Gorins A. Comparative trial of nafoxidine and ethinyloestradiol in advanced breast cancer: an E.O.R.T.C. study. Br Med J. 1975 Jun 28;2(5973):711–713. doi: 10.1136/bmj.2.5973.711. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Kwa H. G., De Jong-Bakker M., Engelsman E., Cleton F. J. Plasma-prolactin in human breast cancer. Lancet. 1974 Mar 16;1(7855):433–435. doi: 10.1016/s0140-6736(74)92385-x. [DOI] [PubMed] [Google Scholar]
  5. Malarkey W. B., Jacobs L. S., Daughaday W. H. Levodopa suppression of prolactin in nonpuerperal galactorrhea. N Engl J Med. 1971 Nov 18;285(21):1160–1163. doi: 10.1056/NEJM197111182852102. [DOI] [PubMed] [Google Scholar]
  6. Minton J. P., Dickey R. P. Prolactin, F.S.H., and L.H. in breast cancer: effect of levodopa and oophorectomy. Lancet. 1972 May 13;1(7759):1069–1070. doi: 10.1016/s0140-6736(72)91249-4. [DOI] [PubMed] [Google Scholar]
  7. Minton J. P. Proceedings: The response of breast cancer patients with bone pain to L-dopa. Cancer. 1974 Feb;33(2):358–363. doi: 10.1002/1097-0142(197402)33:2<358::aid-cncr2820330209>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  8. Pearson O. H., Llerena O., Llerena L., Molina A., Butler T. Prolactin-dependent rat mammary cancer: a model for man? Trans Assoc Am Physicians. 1969;82:225–238. [PubMed] [Google Scholar]
  9. Rozencweig M., Heuson J. C., Bila S., L'Hermite M., Robyn C. Effects of 2-Br-alpha-Ergocryptine, L-dopa and cyclic imides on serum prolactin in postmenopausal women. Eur J Cancer. 1973 Sep;9(9):657–664. doi: 10.1016/0014-2964(73)90008-x. [DOI] [PubMed] [Google Scholar]
  10. Stoll B. A. Brain catecholamines and breast cancer: a hypothesis. Lancet. 1972 Feb 19;1(7747):431–431. doi: 10.1016/s0140-6736(72)90875-6. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES